Concerned about the rare disease "true red blood cell hypertrophy" :P TG-300 approved by FDA orphan drug

True erythropoietin (polycythemia vera, PV) is a bone marrow proliferation tumor, a group of malignant tumors derived from hematopoieticstem cells, characterized by the proliferation of bone marrow cell cloning with different morphological maturityPv differs from other MPNs in the increase dissocyt and is associated with an increased risk ofthrombosisembolism, leukemia conversion, and/or bone marrow fibrosisThe U.SFood and Drug Administration,
Administration of(
FDA) has awarded PTG-300 an orphan drug designation for PV, The Pharmaceuticals announced todayPTG-300 is a synthetic peptide that is currently being clinically developedTrue recently published the preliminary results of Phase II clinical trials in patients with true red blood cell growthSamuel Saks, Chief Medical Officer, said: "The FDA's certification of orphan medicines by Thein is an important milestonePatients with true erythrocytic hyperemia face a high disease burden, and PTG-300 has shown good safety in the treatment of true erythrocyte disease with novel therapeutic mechanisms."